Nothing Special   »   [go: up one dir, main page]

CY1124548T1 - Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου - Google Patents

Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου

Info

Publication number
CY1124548T1
CY1124548T1 CY20211100607T CY211100607T CY1124548T1 CY 1124548 T1 CY1124548 T1 CY 1124548T1 CY 20211100607 T CY20211100607 T CY 20211100607T CY 211100607 T CY211100607 T CY 211100607T CY 1124548 T1 CY1124548 T1 CY 1124548T1
Authority
CY
Cyprus
Prior art keywords
mono
disubtituted
dange
compounds
virus replication
Prior art date
Application number
CY20211100607T
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Jean-François BONFANTI
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Dorothée Alice Marie-Eve BARDIOT
Arnaud Didier M MARCHAND
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of CY1124548T1 publication Critical patent/CY1124548T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε ενώσεις μονο- ή δισυποκατεστημένης ινδόλης, μεθόδους πρόληψης ή θεραπευτικής αντιμετώπισης μολύνσεων από δάγκειο ιό, χρησιμοποιώντας τις εν λόγω ενώσεις και αναφέρεται επίσης σ’ αυτές τις ενώσεις για χρήση ως φάρμακο, προτιμότερα για χρήση ως φάρμακο για τη θεραπευτική αντιμετώπιση ή πρόληψη μολύνσεων από δάγκειο ιό. Η παρούσα εφεύρεση αναφέρεται περαιτέρω σε φαρμακευτικές συνθέσεις ή σκευάσματα συνδυασμού των ενώσεων, σε συνθέσεις ή σκευάσματα για χρήση ως φάρμακο, προτιμότερα για την πρόληψη ή τη θεραπευτική αντιμετώπιση μολύνσεων από δάγκειο ιό. Η εφεύρεση αναφέρεται επίσης σε διαδικασίες για την παρασκευή των ενώσεων.
CY20211100607T 2015-05-08 2021-07-06 Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου CY1124548T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166900 2015-05-08
EP16163342 2016-03-31
PCT/EP2016/059975 WO2016180696A1 (en) 2015-05-08 2016-05-04 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
CY1124548T1 true CY1124548T1 (el) 2022-07-22

Family

ID=56026812

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100607T CY1124548T1 (el) 2015-05-08 2021-07-06 Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου

Country Status (38)

Country Link
US (4) US10696632B2 (el)
EP (2) EP3896072B1 (el)
JP (4) JP6752821B2 (el)
KR (2) KR102610493B1 (el)
CN (3) CN113045476B (el)
AU (2) AU2016259677B2 (el)
BR (1) BR112017023904A2 (el)
CA (1) CA2981845C (el)
CL (1) CL2017002817A1 (el)
CO (1) CO2017012381A2 (el)
CR (2) CR20170490A (el)
CY (1) CY1124548T1 (el)
DK (1) DK3294738T3 (el)
EA (1) EA034978B1 (el)
EC (2) ECSP17073878A (el)
ES (2) ES2877404T3 (el)
GT (1) GT201700234A (el)
HK (2) HK1252446A1 (el)
HR (1) HRP20210675T1 (el)
HU (1) HUE054724T2 (el)
IL (2) IL255430B (el)
JO (2) JOP20160086B1 (el)
LT (1) LT3294738T (el)
MD (1) MD3294738T2 (el)
MX (2) MX2020011156A (el)
NI (1) NI201700137A (el)
PE (2) PE20180232A1 (el)
PH (1) PH12017502000B1 (el)
PL (1) PL3294738T3 (el)
RS (1) RS62029B1 (el)
SG (1) SG10201900315SA (el)
SI (1) SI3294738T1 (el)
SV (1) SV2017005557A (el)
TW (2) TWI744963B (el)
UA (2) UA121332C2 (el)
UY (2) UY36674A (el)
WO (1) WO2016180696A1 (el)
ZA (2) ZA201707524B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6888021B2 (ja) 2016-03-31 2021-06-16 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての置換インドール誘導体
JP6931357B2 (ja) 2016-03-31 2021-09-01 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
MX2018011786A (es) 2016-04-01 2019-05-20 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue.
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20190530A (es) * 2017-05-22 2020-01-24 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
EA039702B1 (ru) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CN114980884A (zh) 2019-11-15 2022-08-30 杨森制药公司 登革热疾病的治疗和预防
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
WO2022094817A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
CN113024440B (zh) * 2021-03-17 2023-05-16 凯莱英医药集团(天津)股份有限公司 连续化合成取代吲哚-2-羧酸的方法
CN117616010A (zh) 2021-06-29 2024-02-27 杨森制药公司 制备(s)-2-(4-氯-2-甲氧基苯基)-2-((3-甲氧基-5-(甲磺酰基)苯基)氨基)-1-(1h-吲哚-3-基)乙烯酮衍生物的方法
WO2023218285A1 (en) 2022-05-12 2023-11-16 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
CN115521307B (zh) * 2022-09-30 2023-09-22 甘肃皓天医药科技有限责任公司 一种5-卤代-7-氮杂吲哚的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830335T2 (de) 1997-10-27 2006-02-02 Eli Lilly And Co., Indianapolis MORPHOLINO-N-ETHYL ESTER PRODROGEN VON INDOL sPLA 2 HEMMER
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
WO2003050295A2 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
ZA200705872B (en) 2005-01-14 2008-09-25 Genelabs Tecnologies Inc Indole derivatives for treating viral infections
EP1853317A2 (en) 2005-02-09 2007-11-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2009149054A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
AU2009283195A1 (en) * 2008-08-18 2010-02-25 Yale University MIF modulators
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
JP5777223B2 (ja) 2010-01-15 2015-09-09 ギリアード サイエンシーズ, インコーポレイテッド フラビウイルス科ウイルスのインヒビター
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
DK3060547T3 (en) 2013-10-23 2018-01-15 Janssen Sciences Ireland Uc CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
PE20161069A1 (es) 2014-01-31 2016-10-22 Bristol Myers Squibb Co Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia
BR112016028537A2 (pt) 2014-06-04 2017-08-22 Hutchinson Fred Cancer Res expansão e enxerto de células-tronco utilizando agonistas de notch 1 e/ou de notch 2
KR102391259B1 (ko) 2014-06-04 2022-04-26 암젠 인크 포유류 세포 배양물을 회수하는 방법
HUE042628T2 (hu) 2014-10-01 2019-07-29 Janssen Pharmaceuticals Inc Mono- vagy diszubsztituált indolok mint dengue vírus replikáció inhibitorok
NO2721243T3 (el) 2014-10-01 2018-10-20
ES2714074T3 (es) * 2014-10-01 2019-05-27 Janssen Pharmaceuticals Inc Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
EP3204517B1 (en) 2014-10-10 2021-08-11 Rutgers, the State University of New Jersey Polymerase chain reaction primers and probes for mycobacterium tuberculosis
JOP20150335B1 (ar) * 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US11096910B2 (en) 2015-07-22 2021-08-24 Max Delbruck-Centrum Fur Molekulare Medizin Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6864001B2 (ja) 2015-11-03 2021-04-21 ゾエティス・サービシーズ・エルエルシー ゾル−ゲルポリマー組成物及びそれらの使用
JP6788683B2 (ja) 2016-03-31 2020-11-25 武田薬品工業株式会社 複素環化合物
JP6888021B2 (ja) 2016-03-31 2021-06-16 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての置換インドール誘導体
JP6931357B2 (ja) 2016-03-31 2021-09-01 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
EP3436457B1 (en) 2016-04-01 2022-07-20 Basf Se Bicyclic compounds
EA039392B1 (ru) 2016-04-01 2022-01-21 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способ лечения рака с применением замещенного аминопуринового соединения
IL296966A (en) 2016-04-01 2022-12-01 Amgen Inc Chimeric flt-3 receptors and methods of using them
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CU20180121A7 (es) 2016-04-01 2019-05-03 Kite Pharma Inc Receptores de antígenos quiméricos y células t
BR112018070260A2 (pt) 2016-04-01 2019-01-29 Amgen Inc receptores quiméricos e métodos de uso dos mesmos
MX2018011786A (es) 2016-04-01 2019-05-20 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue.
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA039702B1 (ru) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CR20190530A (es) 2017-05-22 2020-01-24 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue

Also Published As

Publication number Publication date
UA128183C2 (uk) 2024-05-01
KR102610491B1 (ko) 2023-12-06
TW201704208A (zh) 2017-02-01
CL2017002817A1 (es) 2018-05-11
EA201792429A1 (ru) 2018-02-28
NI201700137A (es) 2019-05-07
PH12017502000A1 (en) 2018-03-26
LT3294738T (lt) 2021-08-25
AU2020273314B2 (en) 2021-10-21
ECSP22023220A (es) 2022-05-31
PE20221579A1 (es) 2022-10-06
JOP20160086B1 (ar) 2021-08-17
MX2017014293A (es) 2018-08-09
JP2018515495A (ja) 2018-06-14
KR102610493B1 (ko) 2023-12-05
IL255430A0 (en) 2017-12-31
KR20210048578A (ko) 2021-05-03
MD3294738T2 (ro) 2021-08-31
CN107873022A (zh) 2018-04-03
CR20200152A (es) 2020-09-08
AU2020273314A1 (en) 2020-12-17
RS62029B1 (sr) 2021-07-30
TWI744963B (zh) 2021-11-01
US20200270209A1 (en) 2020-08-27
CA2981845C (en) 2022-03-08
GT201700234A (es) 2018-11-26
EA034978B1 (ru) 2020-04-14
PE20180232A1 (es) 2018-01-31
AU2016259677A1 (en) 2017-10-26
IL255430B (en) 2020-03-31
UY39706A (es) 2022-05-31
MX2020011156A (es) 2022-04-21
US10696632B2 (en) 2020-06-30
CN113045476A (zh) 2021-06-29
CN111303000A (zh) 2020-06-19
PH12017502000B1 (en) 2018-03-26
EP3896072A1 (en) 2021-10-20
HRP20210675T1 (hr) 2021-06-25
ZA201707524B (en) 2024-06-26
CN107873022B (zh) 2021-03-12
CA2981845A1 (en) 2016-11-17
UY36674A (es) 2016-11-30
CR20170490A (es) 2018-03-08
WO2016180696A1 (en) 2016-11-17
ZA202002435B (en) 2023-03-29
US11827602B2 (en) 2023-11-28
CO2017012381A2 (es) 2018-03-28
JP6752821B2 (ja) 2020-09-09
JP2022166289A (ja) 2022-11-01
HK1252496A1 (zh) 2019-05-31
HK1252446A1 (zh) 2019-05-24
JP6898493B2 (ja) 2021-07-07
ES2941674T3 (es) 2023-05-24
US10919854B2 (en) 2021-02-16
PL3294738T3 (pl) 2021-12-13
AU2016259677B2 (en) 2020-10-01
TWI725969B (zh) 2021-05-01
JP2021138752A (ja) 2021-09-16
IL272814A (en) 2020-04-30
EP3896072B1 (en) 2022-11-16
ES2877404T3 (es) 2021-11-16
US20240182414A1 (en) 2024-06-06
EP3294738A1 (en) 2018-03-21
EP3294738B1 (en) 2021-04-07
KR20180002644A (ko) 2018-01-08
BR112017023904A2 (pt) 2018-07-17
SV2017005557A (es) 2018-06-26
JP7451626B2 (ja) 2024-03-18
JP2020125316A (ja) 2020-08-20
SI3294738T1 (sl) 2021-08-31
US20180346419A1 (en) 2018-12-06
HUE054724T2 (hu) 2021-09-28
DK3294738T3 (da) 2021-06-28
IL272814B (en) 2021-02-28
ECSP17073878A (es) 2018-02-28
JP7132399B2 (ja) 2022-09-06
NZ736934A (en) 2023-11-24
UA121332C2 (uk) 2020-05-12
US20210171462A1 (en) 2021-06-10
CN113045476B (zh) 2024-07-16
TW202041499A (zh) 2020-11-16
CN111303000B (zh) 2023-11-28
JOP20210109A1 (ar) 2023-01-30
SG10201900315SA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1121874T1 (el) Παραγωγα μονο- ή διυποκατεστημενου ινδολιου ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου
CY1121972T1 (el) Mono- ή διυποκατεστημενα ινδολια ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
CL2018002729A1 (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue.
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201892219A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201992295A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге